Happy Spring!

Hard to believe that the much anticipated 10th International Meeting of Pediatric Endocrinology is now less than 6 months away! Under David Allen’s leadership, the organizing committee has done an outstanding job in putting together what promises to be an absolutely first rate program with broad appeal! Watch for registration details, which will be available soon. We are always pleased to welcome new members (see below) and to highlight important educational and career development offerings to our membership, as described below. I am also grateful to the Obesity Committee for their careful review of a report of obesity trends in a large national data set, and to the Drug and Therapeutics Committee for their thorough review of three new insulin formulations and for their timely update on potential safety concerns associated with long-term treatment of gonadotropin releasing hormone agonists.

Finally, please ensure the ability of PES to continue to be relevant in our professional lives—whether your priorities are supporting research, educational offerings, career development, quality improvement, or advocacy for patients, families, and fellow providers, please contribute to our $45-4-45 campaign. Your tax deductible gifts will truly make a difference!

Thank you!

Welcome New Members:

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nadia Merchant</td>
<td>Texas Childrens Hospital</td>
</tr>
<tr>
<td>Chanthu Pillai</td>
<td>The University of Texas-Houston</td>
</tr>
<tr>
<td>Lina Alkhaled</td>
<td>Rainbow Babies and Childrens Hospital</td>
</tr>
<tr>
<td>Rachel Whooten</td>
<td>MGH</td>
</tr>
<tr>
<td>Adam Adamidis</td>
<td>Baystate Childrens Hospital</td>
</tr>
<tr>
<td>Maria Chang</td>
<td>Stanford University</td>
</tr>
<tr>
<td>Sumeet Arora</td>
<td>SUNY Downstate Medical Center</td>
</tr>
<tr>
<td>Zoe Raleigh</td>
<td>University of Utah</td>
</tr>
<tr>
<td>Mansa Krishnamurthy</td>
<td>Cincinnati Children's Hospita Medical Center</td>
</tr>
<tr>
<td>Marwan Bakhach</td>
<td>Childrens Hospital of Los angeles</td>
</tr>
<tr>
<td>Harpreet Gill</td>
<td>Children's Hospital of Eastern Ontario</td>
</tr>
<tr>
<td>Christy Foster</td>
<td>University of Tennessee Health Science Center</td>
</tr>
<tr>
<td>Massiel Sarmiento</td>
<td>Connecticut Children's Medical Center</td>
</tr>
<tr>
<td>Huay-Lin Lo</td>
<td>University of Texas Southwestern</td>
</tr>
<tr>
<td>Kristina Cossen</td>
<td>Emory University</td>
</tr>
<tr>
<td>Erin Burry</td>
<td>Hospital for Sick Children</td>
</tr>
<tr>
<td>Rochelle Wilson</td>
<td>UT Southwestern/ Children's Health</td>
</tr>
<tr>
<td>Stephen Zborovski</td>
<td>Hospital for Sick Children</td>
</tr>
<tr>
<td>Komal Vora</td>
<td>John Hunter Children's Hospital/</td>
</tr>
<tr>
<td></td>
<td>The Children's Hospital at Westmead</td>
</tr>
<tr>
<td>Sisi Namoc</td>
<td>Instituto Nacional de Salud del Niño</td>
</tr>
<tr>
<td>Suttikarn Santiwatana</td>
<td>Faculty of Medicine Ramathibodi Hospital</td>
</tr>
<tr>
<td></td>
<td>Mahidol University</td>
</tr>
<tr>
<td>Pamela Smith</td>
<td>Washington University in St. Louis</td>
</tr>
</tbody>
</table>

The 10th International Meeting - Celebrating our global pediatric endocrinology community
The 10th International Meeting is rapidly approaching. Registration for the meeting is due to open on April 3rd.

**Special Interest Groups**
A number of Special Interest Groups from the various international pediatric endocrine societies will be holding “co-meetings” at the 10th International Meeting. Some of these meetings will include a brief “organizational” meeting to facilitate the formation of SIG’s supported by the Pediatric Endocrine Society. The date and time for the Special Interest Groups have been confirmed.

Date: Thursday September 14th
Time: 8:30 am – 12:00 noon

Click here for a full list of the SIGS complete with a current description and meeting agenda: [http://internationalmeeting2017.org/docs/SIG_Descriptions.pdf](http://internationalmeeting2017.org/docs/SIG_Descriptions.pdf)

**Now Available! Travel Awards**
PES is pleased to offer Travel Grants to Fellows attending the 10th International Meeting of Pediatric Endocrinology. Applicants must be members of the Pediatric Endocrine Society to apply. Applications are now open! Click here to apply.

**2017 PES Ethics Essay Competition for Trainees**
The Pediatric Endocrine Society Ethics Committee is hosting the fifth annual essay competition aimed at pediatric endocrinology fellows and pediatric residents. We invite essays of up to 1000 words detailing a case or case series, the ethical conundrums that arose, and a description of how the author wrestled with and resolved the dilemma. The essays should address the four pillars of medical ethics: beneficence, non-maleficence, justice, and autonomy. The essays will be read and judged by the members of the PES Ethics Committee. A $500 prize will be awarded to the first place essay writer. The winner will also have a chance to present their essay as a poster presentation at the PES 10th International Meeting of Pediatric Endocrinology.

Please click here for more information
Please click here for an application

**NOW OPEN! PES 2017 Board Review Course**

**September 11-13, 2017, in Arlington, VA**
Join colleagues for interactive lectures covering the ABP Pediatric Endocrine Content Outline. The Course will be held at Crystal Gateway Marriott in Arlington, VA prior to the 10th International Meeting of Pediatric Endocrinology.

Attendees are responsible for making their own hotel reservations. Once you have registered for the Board Review Course you will be sent a link with hotel reservation information. PES has set aside a block of rooms at a special rate of $259/night for those who wish to stay at the hotel where the Course will take place. Group pricing is good until August 21, 2017 - please plan accordingly.

Click here to register for the PES 2017 Board Review Course.

Click here to make your hotel reservations.

**PES Advantage Leadership Development Certificate Program**
The PES Leadership Advantage 2017 courses will also be held on September 13th just prior to the International Meeting. Both Module 1 & and the recently developed Module 2 will be offered this year. Registration will open in April 2017.

PES Leadership Advantage Module 2 is the next installment in a series of topics to promote the development of leadership skills. When fully developed, the course will have four Modules that can be completed in any order for the PES Leadership Advantage Certificate.
Topics for Module 2:

- Decision Making – Leadership vs. Clinical Approaches
- Coaching and Mentoring for Performance
- Explore the Elements of Positive Culture & High Engagement

For those that missed the PES Leadership Advantage Module One last year, it will also be offered at the international PES conference in September. Click Here to see the PES Leadership Advantage Module 1 overview.

Registration for the PES Leadership Advantage Course 2017 will open soon!

Obesity-Linked Diagnoses on the Rise Among Kids And Teens:

A recent report from Fair Health on trends in childhood obesity was picked up and reported by several news agencies. This study found that the rates of claims for obesity and type 2 diabetes have increased in the pediatric population between 2011-2015, inclusive of ages 0 to 22 years. Interestingly, while there were more obesity-related claims for females than males in almost every age group, type 2 diabetes mellitus related claims were more common in males than females. There were also increasing trends in claims for associated comorbidities such as hypertension, obstructive sleep apnea and pre-diabetes. A state by state analysis is included in the report. Members of the PES Obesity Committee who reviewed the report indicated that this was a well written and interesting report of obesity trends in a large national dataset. It is notable that across the United States providers are increasingly diagnosing and managing these disease states in children and young adults. However, the committee had some concerns about the use of coding to define the disease states, the discrepancies in the information as compared to prior data (CDC, SEARCH, etc.) and particularly the reported numbers for obesity and type 2 diabetes mellitus in the youngest age group. Specifically there were concerns about changes in coding trends during the study period and the changing definitions of obesity in young children.

Please click here for details of the review.

Committee Corner:

Drug and Therapeutics Committee – Update on Insulin

The PES Drug and Therapeutics committee has provided a brief review of three new insulin formulations that have recently become available to our patients. These include Basaglar (another brand of glargine), Tresiba (insulin degludec) and Toujeo (a concentrated version of glargine). The D & T review includes a brief summary of the new insulin products as well as references. The review and references can be found on the PES website by clicking here.

On Behalf of the Drug & Therapeutics Committee: Updated Information About Safety Events after Gonadotropin Releasing Hormone Agonist Therapy.

On 2/2/17, Kaiser Health News published an article raising concerns about potential long-term side effects of leuprolide acetate for depot suspension in women previously treated with this medication and stating that the FDA was “currently conducting a specific review of nervous system and psychiatric events in association with the use of GnRH agonists, [a class of drugs] including Lupron, in pediatric patients.”

Since then, we have conducted a literature search and contacted the manufacturers of GnRH agonists in the U.S. and pediatric endocrinology colleagues in the US, UK, EU and South America to inquire about any new safety issues. We also spoke with representatives of the FDA who acknowledged that a Tracked Safety Issue (TSI) has been initiated for non-urgent review of potential safety concerns in this class of medications.

After further review of available information, we do not feel that there is any new safety concern with GnRH agonists that should change our prescribing practices at this time.

As always, we recommend that any unexpected medication adverse events be reported to the FDA.
The Rare Bone Disease Alliance

The Rare Bone Disease Alliance is a new organization which will work to educate physicians, expand research on rare bone disease and assist rare bone disease patients, patient organizations, and family members. The Alliance will encourage professional, medical, and scientific societies to expand their educational programs on rare bone disease and will organize its own meetings and workshops. The Alliance is built on the progress and success of The Rare Bone Disease Patient Network (RBDPN), a coalition of patient organizations which was founded in 2006.

Alliance participants include rare bone disease physician and scientific leaders, patient organizations, and pharmaceutical companies working in the rare bone field. Click here for more information: www.rbdalliance.org

Camps

PES is pleased to share the following information on various upcoming camps! Please note that PES was not involved in the development of any camp or camp website, and a listing here does not imply endorsement by PES, but rather a resource for patients and families. Are you a pediatric endocrine Fellow looking for a camp volunteer opportunity? We invite you to visit the websites listed on our camps page for more information. https://www.pedsendo.org/patients_families/camps/index.cfm

If you know of other camps that you would like listed here, please contact us at info@pedsendo.org

PES turns 45!
$45 – 4 – 45!

This year marks the 45th anniversary of the founding of our Society! We are a robust and active organization that continues to have a significant impact in advancing and promoting the endocrine health of children and adolescents. With a membership of close to 1200, we are committed to our vision of being the professional home and voice of pediatric endocrinology in North America.

Please click here to contribute to our $45 for 45 years campaign to help advance our new Strategic Plan that will carry us to our 50-year anniversary celebration! Click here

Special Thanks to those that have already contributed!

Dates to remember:

- International Scholar Program: The deadline for applications is April 1, 2017 for 2017 awards for the applicant to be in North America in the spring of 2018. Please click here for details.
- Travel Awards now being accepted! Click here to apply.
- Registration for the 10th International Meeting of Pediatric Endocrinology due to open April 3rd!
- Board Review Course Registration now open! Click here to register.

Historical Tidbit provided by Walter L. Miller
Contemporary pediatric endocrinologists will quickly suspect adrenocortical carcinoma (ACC) in a 3-6 year old girl with severe Cushingoid features, growth arrest and virilism. The first known published case of apparent ACC was that describing Hannah Taylor (1682-1688), a 6-year old whose autopsy was reported by Henry Sampson (Philosophical Transactions 19:80-82, 1697); this fascinating paper was reproduced and its historical context discussed recently (J Steroid Biochem Mol Biol 165:109-113, 2017). Fuller Albright’s mid-20th century perspective on ACC is seen in NEJM 241:874-877, 1949. Most pediatric ACC is caused by mutations in the p53 tumor-suppressor gene, usually in association with Li-Fraumeni syndrome (Endocr Rev 35: 282–326, 2014). Early diagnosis can permit surgical cure, but prognosis in metastatic disease remains poor.

Any PES member can contribute a tidbit! Send yours to Walter L Miller (Chair of the History Committee) at wmlab@ucsf.edu

Sincerely,

Stephen M. Rosenthal, MD
PES President

Bruce Boston, MD
PES Board Member